Keyword: Sangamo BioSciences
Winson Tang is accused of telling a friend about a 2014 agreement between Sangamo and Biogen before the news became public.
The €72 million takeover positions Sangamo to move a CAR-carrying regulatory T cell therapy into testing in solid organ transplant patients next year.
Human Longevity CFO/COO departs after scandal; Sangamo loses another top executive; McCann Health fires chief creative for conduct violation and more.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.
Sangamo's SVP and Chief Technology Officer Michael Holmes is resigning to join an unnamed biotech startup.
Curt Herberts, who spearheaded a number of deals as Sangamo Therapeutics' chief business officer, is joining Senti Bio as its new CFO and CBO.
There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.
Two recent advances are focused on using engineered T cells and drug nanocrystals to combat the HIV “reservoirs” that hide in the body and cause the disease to re-emerge.
After deals and acquisitions with Spark Therapeutics and Bamboo, Pfizer is once again looking to bolster its rare and gene therapy pipeline as it outlines a new drug pact with Sangamo.
Gene editing pioneer Sangamo BioSciences has its sights set on curing hemophilia, a rare disorder in which the blood doesn't clot normally.